Vischer advises Atanis Biotech on financing round
Vischer advised Atanis Biotech, a Swiss biotechnology company, to successful completion of an oversubscribed financing round.
The financing round
The proceeds from this operation will fund the European and North-American marketing campaigns for Atanis’s “Fast-Pase” allergy test, a diagnostic tool positioned as a safer and more accurate allergy testing solution compared to the market standard.
The capital round in question was led by Spectrum Moonshot Fund and further supported by other investors active in the allergy diagnostics field.
Specialising in advanced allergy diagnostics, Atanis was incorporated as a spinoff of the University of Bern in June 2021.
The team
The Visher’s team handling the operation was composed by parter Gian-Andrea Caprez (pictured) and senior associate Sandro Bernet (both corporate/M&A)